King Luther Capital Management Corp Buys 457,150 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

King Luther Capital Management Corp raised its stake in shares of scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 48.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,393,525 shares of the company's stock after buying an additional 457,150 shares during the period. King Luther Capital Management Corp owned about 3.89% of scPharmaceuticals worth $8,737,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Raymond James & Associates raised its holdings in scPharmaceuticals by 5.7% in the 3rd quarter. Raymond James & Associates now owns 81,672 shares of the company's stock worth $582,000 after acquiring an additional 4,420 shares during the period. Worth Venture Partners LLC raised its holdings in scPharmaceuticals by 5.3% in the 3rd quarter. Worth Venture Partners LLC now owns 539,665 shares of the company's stock worth $3,842,000 after acquiring an additional 27,328 shares during the period. Tejara Capital Ltd bought a new position in scPharmaceuticals in the 3rd quarter worth $722,000. AIGH Capital Management LLC raised its holdings in scPharmaceuticals by 7.6% in the 3rd quarter. AIGH Capital Management LLC now owns 2,207,009 shares of the company's stock worth $15,714,000 after acquiring an additional 155,204 shares during the period. Finally, Rubric Capital Management LP raised its holdings in scPharmaceuticals by 234.3% in the 3rd quarter. Rubric Capital Management LP now owns 2,713,287 shares of the company's stock worth $19,319,000 after acquiring an additional 1,901,770 shares during the period. Institutional investors own 89.52% of the company's stock.

scPharmaceuticals Stock Performance

Shares of NASDAQ:SCPH traded down $0.29 on Wednesday, hitting $3.54. 475,182 shares of the company were exchanged, compared to its average volume of 229,101. The company's 50 day moving average price is $4.78 and its two-hundred day moving average price is $5.35. scPharmaceuticals Inc. has a one year low of $3.46 and a one year high of $11.75. The company has a debt-to-equity ratio of 1.60, a quick ratio of 5.44 and a current ratio of 6.21. The firm has a market capitalization of $127.62 million, a price-to-earnings ratio of -2.39 and a beta of 0.09.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last issued its earnings results on Tuesday, May 14th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.09. scPharmaceuticals had a negative net margin of 327.29% and a negative return on equity of 132.39%. The business had revenue of $6.10 million for the quarter, compared to analyst estimates of $6.50 million. During the same period in the previous year, the business earned ($0.30) EPS. Research analysts expect that scPharmaceuticals Inc. will post -1.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and issued a $18.00 target price on shares of scPharmaceuticals in a report on Wednesday, May 15th.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.